BIO Deutschland and EY publish key figures of the biotechnology sector in 2019
In 2019, the biotechnology sector in Germany has developed much more dynamically than in previous years. Companies achieved double-digit growth rates in almost all areas: turnover rose by ten percent to 4.87 billion euros, the number of employees by 16 percent to 33,706 and research and development expenditure by as much as 21 percent to 1.79 billion euros. This development was primarily driven by the listed companies, which raised the turnover by 18 percent, the number of employees by 26 percent and R&D spending by 58 percent. However, the figures also reflect the fact that BioNTech has been listed on the stock exchange last year – and together with QIAGEN and Evotec alone is responsible for 40 per cent of total revenues. These are the results of the German Biotechnology Report 2020 published by the consulting company EY in cooperation with BIO Deutschland.
The figures were published together with the EY Biotechnology Report at a virtual press conference on 27th April.
The text of the press release on the press conference and the EY Biotechnology Report for download (in German) can be found here: www.biodeutschland.org/de/pressemitteilungen/biotechnologie-in-deutschland-entwickelt-sich-dynamisch-finanzierung-in-der-breite-weiter-schwierig.html?year=2020